Eli Lilly (LLY) Assets (2009 - 2026)

Eli Lilly has reported Assets for 18 years, with the latest figure at $116.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 30.41% year-over-year to $116.6 billion; the trailing twelve-month figure through Mar 2026 stood at $116.6 billion (up 30.41% YoY), and the FY2025 full-year result was $112.5 billion, up 42.89% from the prior year.
• Assets for Q1 2026 stood at $116.6 billion, up from $112.5 billion in the prior quarter.
• The five-year high for Assets was $116.6 billion in Q1 2026, with the low at $46.9 billion in Q1 2022.
• Historically, Assets has averaged $73.3 billion across 5 years, with a median of $64.0 billion in 2023.
• Annual changes were most pronounced in 2022 — Assets decreased 1.56% — and 2025, when it jumped 52.02%.
• Eli Lilly's Assets stood at $49.5 billion in 2022, then grew by 29.33% to $64.0 billion in 2023, then grew by 22.98% to $78.7 billion in 2024, then jumped by 42.89% to $112.5 billion in 2025, then climbed by 3.65% to $116.6 billion in 2026.
• The last three Assets figures came in at $116.6 billion (Q1 2026), $112.5 billion (Q4 2025), and $114.9 billion (Q3 2025), per Business Quant data.